References
- ThompsonPDClarksonPMRosensonRSNational Lipid Association Statin Safety Task Force Muscle Safety Expert PanelAn assessment of statin safety by muscle expertsAm J Cardiol2006978A69C76C
- ArmitageJBowmanLWallendszusKStudy of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupLancet2010376975316586921067805
- US Food Drug AdminsitrationFDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury Avaialble from http://www.fda.gov/Drugs/DrugSafety/ucm283137.htmAccessed Apr 4, 2016
- KostapanosMSMilionisHJElisafMSRosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemiaAm J Cardiovasc Drugs2010101112820104931
- BhomeRPennHRhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interactionDiabet Med20122969369422023482
- WilliamsDFeelyJPharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitorsClin Pharmacokinet20024134337012036392
- LauYYHuangYFrassettoLBenetLZEffect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteersClin Pharmacol Ther20078119420117192770
- Lipitor (atorvastatin calcium) [package insert]New York, NYParke-Davis2015
- GrahamDJStaffaJAShatinDIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsJAMA2004292212585259015572716
- Sitagliptin (Januvia) [package insert]Whitehouse station, NJMerk and Co Inc2015
- WilkeRARamseyLBJohnsonSGThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyClin Pharmacol Ther201292111211722617227
- NiemiMPasanenMKNeuvonenPJOrganic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptakePharmacol Rev201163115718121245207
- KalliokoskiANiemiMImpact of OATP transporters on pharmacokineticsBr J Pharmacol2009158369370519785645
- PasanenMKNeuvonenMNeuvonenPJNiemiMSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenet Genomics2006161287387917108811
- OmarMAWilsonJPFDA adverse event reports on statin-associated rhabdomyolysisAnn Pharmacother20023628829511847951
- ThompsonPDClarksonPKarasRHStatin-associated myopathyJAMA2003289131681169012672737
- StaffaJAChangJGreenLCerivastatin and reports of fatal rhabdomyolysisN Engl J Med200234653954011844864
- DiGregorioRVPasikhovaYRhabdomyolysis caused by a potential sitagliptin-lovastatin interactionPharmacotherapy200929335235619249953
- KaoDPKohrtHEKuglerJRenal failure and rhabdomyolysis associated with sitagliptin and simvastatin useDiabet Med200825101229123019046202